Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options

Wednesday, June 27, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

OSLO, Norway, June 27, 2018 /PRNewswire/ --

A participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO)

previous employee share option program, not being a primary insider, has exercised a total number of 41,246 options through exercise of a corresponding number of free-standing warrants. 10,413 of the shares are exercised at a strike price of NOK
14.24
per share, and 30,833 of the shares are exercised at a strike price of NOK 34 per share. Each free-standing warrant gives the right to receive one share in the Company.

Following exercise of the 41,246 free-standing warrants, the Company's registered share capital was increased by NOK 8,249.2 through issuance of 41,246 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 1,196,603. Following the share capital increase the Company has a share capital of NOK 9,817,129.6 divided on 49,085,648 shares, each with a par value of NOK 0.20.

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is BetalutinŽ, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of BetalutinŽ in core markets. Further information about the Company can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

CONTACT:

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44-7561-431-762

Email: ir@nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--increased-share-capital-following-exercise-of-employee-share-options,c2558977

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-increased-share-capital-following-exercise-of-employee-share-options-300673159.html

SOURCE Nordic Nanovector



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store